Skip to main content
Fig. 3 | BMC Endocrine Disorders

Fig. 3

From: The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile

Fig. 3

Oral glucose tolerance test (OGTT) after 4 and 8 weeks of treatment. The incremental area under the curve (iAUC) shown for blood glucose (a and c) and plasma insulin (b and d) during OGTT after 4 and 8 weeks, respectively. n = 8–10 rats per group. Statistical analysis between groups were performed as a one-way ANONA followed by Tukey’s post-hoc test (c) and as Kruskal Wallis test followed by Dunn’s post-hoc test (a, b, d) with the following annotations: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, #P < 0.05, ##P < 0.01 vs. liraglutide (200 μg/kg), §P < 0.05, §§P < 0.01 vs. liraglutide (400 μg/kg), ¤ P < 0.05 vs. KBP-089 (0.625 μg/kg). All data are means ± SEM

Back to article page